Clinical experience with apraclonidine 0.5%.

Abstract

PURPOSE:

This study describes our long-term experience with apraclonidine 0.5% in the treatment of chronic glaucoma in clinical practice.

METHODS:

A retrospective review was performed of all consecutive patients treated with apraclonidine 0.5%, specifically studying the magnitude of IOP reduction, incidence of allergic reaction, frequency of ineffectiveness, and its additivity to other anti-glaucoma medications. Patients previously treated with this agent or in whom multiple simultaneous medication changes were made were excluded.

RESULTS:

A total of 174 patients were included in this study and followed up to 24 months. For 38 patients (21%), the drug was found to be ineffective at some point during the study. A similar number of patients developed an allergic reaction to the medication. Intraocular pressure lowering ranged from 19 to 26% overall, and 22.5 to 29% in those responding to apraclonidine 0.5%.

CONCLUSION:

In this study, apraclonidine 0.5% was shown to be effective in reducing intraocular pressure, both for short-term situations and for longer periods of treatment, up to 24 months.

• Authors: R L Gross, A Pinyero, S Orengo-Nania
• Journal: Journal of glaucoma (J Glaucoma) Vol. 6 Issue 5 Pg. 298-302 (Oct 1997) ISSN: 1057-0829 [Print] United States
• PMID: 9327348 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Adrenergic alpha-Agonists
• apraclonidine
• Clonidine

Topics

• Adolescent
• Adrenergic alpha-Agonists (therapeutic use)
• Adult
• Aged
• Aged, 80 and over
• Child
• Chronic Disease
• Clonidine (administration & dosage, analogs & derivatives, immunology, therapeutic use)
• Drug Hypersensitivity (immunology)
• Eye (immunology)
• Female
• Glaucoma (drug therapy, physiopathology)
• Humans
• Intraocular Pressure (drug effects)
• Male
• Middle Aged
• Osmolar Concentration
• Retrospective Studies